Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits. It focuses on the exploration and development of Skaergaard project located in Southeast Greenland. The company is also involved in the development of KLTO-202, a gene therapy for the treatment and prevention of amyotrophic lateral sclerosis; and KLTO-101 for the treatment or prevention of Alzheimer's disease, as well as therapies to treat Parkinson's and other age-related disorders. The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026. Greenland Mines Ltd is based in Charlotte, North Carolina.